Luigi Stasi, director of medicinal chemistry department at Rottapharm, said: “We are delighted to start an FTE-based collaboration with Selvita. We are keen to take advantage of Selvita’s know-how to support the progression of our drug discovery pipeline. We are looking forward to a very fruitful and effective cooperation.”
Pawel Przewiezlikowski, CEO of Selvita, said: “We are very pleased and honoured that we can cooperate with Rottapharm Madaus. Working for Rottapharm Madaus on this project is expected to enable us to take a full advantage of our scientists and new facilities, and I truly believe we can deliver exactly what Rottapharm Madaus needs. I’m looking forward to this cooperation very much.”
Rottapharm R&D is focused on therapeutic areas such as: rheumatology, gynaecology, urology, gastroenterology, bronchopneumology, psychiatry and oncology.
Selvita Group is a Polish, privately-owned, biotechnology company engaged in the drug discovery services.